Seventeen children with acute myelocytic leukemia were treated with a combination of 6-azauridine, 6-mercaptopurine, and vincristine. Twelve attained complete bone marrow remission, and 2 achieved good partial remissions. For maintenance therapy, patients who attained remission were randomized into 2 groups: one received 6-mercaptopurine alone; the other received a combination of 6-mercaptopurine, 6-azauridine, and vincristine. The median duration of hematologic remission in these groups was 7 and 6 months, respectively. Meningeal leukemia developed in 8 of 15 patients. The overall median survival time was 8 months; for those who attained remission it was 10.5 months. The combination of 6-azauridine, 6-mercaptopurine, and vincristine was effective for remission induction of acute myelocytic leukemia in children.